Jul 27, 2020
Evolus to Report Second Quarter 2020 Financial Results and Provide a Business Update on Monday, August 10, 2020
Management will host a conference call and live webcast to discuss Evolus’ financial results at
The dial-in numbers for the conference call are (866) 916-2317 for domestic callers and (703) 925-2662 for international callers. The conference ID is 7575816.
A replay of the call will be available following its completion through
A live audio webcast of the call will be available on the Investor Relations page of the
Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. In 2019, the U.S. Food and Drug Administration approved Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau® is powered by Evolus' unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today. Visit us at: http://www.evolus.com.
Jeuveau® is a registered trademark of
Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.
Vice President, Finance, Investor Relations &